Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety and pharmacokinetic study of NMB58 (flurpiridaz (18F)) in healthy Japanese adult males
jRCT2080224522Phase 1Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Jan 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Flurpiridaz F 18 in cardiac perfusion defect, sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Safety and tolerability of NMB58 and Pharmacokinetics of NMB58. Started Jan 2019; status: completed.
02
Drugs
Flurpiridaz F 18
03
Conditions
cardiac perfusion defect
Beyond the preview
Go deeper on jRCT2080224522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224522.